Outcome of Board Meeting

September 24, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Outcome of Board Meeting held on September 24, 2026 Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”) Dear Sir/ Madam, Please take note that the Board of Directors in their meeting held today i.e. September 24, 2026, inter-alia considered and approved the acquisition of 70% stake in SN Genelab Private Limited (“SN Gene”) from its existing Shareholders. Post acquisition, SN Gene shall become a Subsidiary of the Company. The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time is enclosed herewith as “Annexure – A”. The Board Meeting commenced at 04:40 P.M. (IST) and concluded at 05:11 P.M. (IST). We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl.: As above Annexure-A DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023: SN Particulars Acquisition of Company 1 Name of the target entity, details in brief SN Genelab Private Limited (“SN Gene”) such as size, turnover etc. Turnover: FY 2026: 57.96 Crores FY 2025: 53.36 Crores FY 2024: 43.27 Crores 2 Whether the acquisition would fall within No, the proposed acquisition does not fall related party transaction(s) and whether within the ambit of related party transaction(s). the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” 3 Industry to which the entity being Diagnostics - Genomics acquired belongs 4 Objects and impact of acquisition To strengthen the Company’s expertise in (including but not limited to, disclosure genomics and broaden its portfolio of of reasons for acquisition of target advanced diagnostic services. entity, if its business is outside the main line of business of the listed entity) 5 Brief details of any governmental or Not Applicable regulatory approvals required for the acquisition 6 Indicative time period for completion of The transaction will be completed by the acquisition November 30, 2026. 7 Consideration - whether cash Cash Consideration consideration or share swap or any other form and details of the same 8 Cost of acquisition and/or the price at Upto INR 168 Crores plus certain which the shares are acquired performance linked earn out capped at INR 31.5 Crores for 70% stake 9 Percentage of shareholding / control Acquisition of 70% stake from existing acquired and / or number of shares shareholders of SN Gene acquired 10 Brief background about the entity SN Gene was incorporated on December 16, acquired in terms of products/line of 2013, in the State of Gujarat and is engaged business acquired, date of in business of providing Diagnostics - incorporation, history of last 3 years Genomics services. turnover, country in which the acquired entity has presence and any other Turnover: As mentioned in Clause 1 above significant information (in brief)